Evgen reported full-year results to end March 2023 with a pre-tax loss of £5.0m (FC est. £4.1m), driven by higher R&D and CMC spend. The consequent higher R&D tax credits reduced the net loss to £4.0m (FC est. £3.5m) resulting in net cash of £5.0m (FC est. £5.5m). Data readouts in 2023 should drive key value points and include Phase I PD/PK data for new Suforadex formulation and relevant preclinical data for SFX-01 as (i) a radiosensitising agent in cancer radiotherapy, (ii) as a treatment in CD ....
07 Jun 2023
Evgen Pharma - FY 2023 finals
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - FY 2023 finals
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
07 Jun 2023 -
Author:
Mark Brewer -
Pages:
13
Evgen reported full-year results to end March 2023 with a pre-tax loss of £5.0m (FC est. £4.1m), driven by higher R&D and CMC spend. The consequent higher R&D tax credits reduced the net loss to £4.0m (FC est. £3.5m) resulting in net cash of £5.0m (FC est. £5.5m). Data readouts in 2023 should drive key value points and include Phase I PD/PK data for new Suforadex formulation and relevant preclinical data for SFX-01 as (i) a radiosensitising agent in cancer radiotherapy, (ii) as a treatment in CD ....